



***Corresponding author:** Teo James, Department of Nephropathy and Hemodialysis, First Affiliated Hospital of Harbin Medical University, China, E-mail: teojames@yahoo.com

Received: 28-Jun-2023, Manuscript No. asoa-23-107934; **Editor assigned:** 30-Jun-2023, PreQC No. asoa-23-107934(PQ); **Reviewed:** 14-Jul-2023, QC No. asoa-23-107934; **Revised:** 20-Jul-2023, Manuscript No. asoa-23-107934(R); **Published:** 27-Jul-2023, DOI: 10.4172/asoa.1000221

Citation: James T (2023) Coronary Microvascular Dysfunction in Atherosclerosis: Pathogenesis, Non-Invasive Screening, and Therapeutic Approaches. *Atherosclerosis Open Access* 8: 221.

Copyright: ©

is emphasizes the burden of inflammation, a distinguishing feature of vulnerable plaques. Importantly, FAI values correlate with the gold standard perivascular inflammation imaging method, PET-CT with ^{18}F -NaF uptake, as evidenced in a recent study of stable patients with high-risk plaques. Evaluating pericoronary adipose tissue may enhance the assessment of highly stenotic atherosclerotic plaques and improve their evaluation by CCTA, with higher FAI values indicating more hemodynamically significant stenosis. In the context of acute myocardial infarction, FAI has demonstrated potential utility, showing higher values around culprit lesions compared to non-culprit lesions. Notably, during follow-up evaluations, FAI around the culprit lesion decreased from baseline, reaching values similar to those detected around stable atherosclerotic regions [12,13]. This underscores FAI's ability to detect acute changes in the inflammatory burden of pericoronary fat, displaying favorable discrimination ability (AUROC = 0.70). Additionally, Oikonomou et al. have described the fat radiomic profile (FRP) of stable pericoronary fat, revealing changes in comparison to follow-up CCTA imaging. Pharmacologic interventions may play a role in modulating the changes observed in pericoronary fat detected by FAI. Drugs such as aspirin, statins, or biologic therapies with anti-inflammatory agents could be implicated in influencing FAI values [14]. This highlights the potential of FAI as a valuable tool for monitoring treatment responses and assessing the effectiveness of anti-inflammatory therapies in patients with CMVD and other cardiovascular conditions. Weight status also significantly influences the development and progression of atherosclerotic disease [15]. Obesity, characterized by excessive expansion of visceral white adipose tissue, known as adiposopathy, involves various detrimental effects, including chronic low-grade inflammation and disrupted lipid metabolism. In particular, epicardial adipose tissue accumulates near the heart and is closely associated with impaired myocardial microcirculation and cardiac abnormalities in obese individuals.

The interplay between obesity-related factors and their impact on cardiovascular health underscores the importance of understanding and managing weight status as part of a comprehensive approach to prevent and manage atherosclerotic disease.

Discussion

The discussion section of this article thoroughly explores the findings and implications of the research presented. The identified genetic determinants of Lp(a) levels, particularly the role of the LPA gene and the influence of single nucleotide polymorphisms (SNPs) and KIV2 repeats on Lp(a) isoform size heterogeneity, are highlighted for their clinical relevance in predicting cardiovascular risk, especially in the context of coronary artery disease (CAD) and degenerative aortic valve stenosis (DAS). The multifaceted mechanisms by which Lp(a) affects cardiovascular pathogenesis, including its pro-atherogenic properties and thrombogenic nature, are discussed in detail. The potential implications of chronic low-grade inflammation in coronary atherosclerosis and the role of Lp(a) near the thorax are also explored.

decrease emphasis on the potential role of inflammation in the pathogenesis of cardiovascular disease.

Conflict of Interest

Author declares no conflict of interest.

References

1. Kojima K, Kimura S, Hayasaka K, Mizusawa M, Misawa T, et al. (2019) Aortic plaque distribution, and association between aortic plaque and atherosclerotic risk factors: an aortic angiography study. *J Atherosclerosis Thromb* 26:997-1006.
2. Komatsu S, Yutani C, Ohara T, Takahashi S, Takewa M, et al. (2018) Angioscopic evaluation of spontaneously ruptured aortic plaques. *J Am Coll Cardiol* 25:2893-2902.
3. Nasiri M, Janoudi A, Vanderberg A, Frame M, Flegler C, et al. (2015) Role of cholesterol crystals in atherosclerosis is unmasked by altering tissue preparation methods. *Microsc Res Tech* 78:969-974.
4. Komatsu S, Yutani C, Takahashi S, Takewa M, Ohara T, et al. Debris collected in-situ from spontaneously ruptured atherosclerotic plaque invariably contains large cholesterol crystals and evidence of activation of innate inflammation: Insights from non-obstructive general angiography. *Atherosclerosis* 352:96-102.
5. Abela GS (2010) Cholesterol crystals piercing the arterial plaque and intima trigger local and systemic inflammation. *J Clin Lipidol* 4:156-164.
6. Roberts JC, Moses C, Wilkins RH (1959) Autopsy studies in atherosclerosis I. Distribution and severity of atherosclerosis in patients dying without morphologic evidence of atherosclerotic catastrophe. *Circulation* 2:511-519.
7. Berezin A, Zulli A, Kerrigan S, Petrovic D, Kruzliak P (2015) Predictive role of circulating endothelial-derived microparticles in cardiovascular diseases. *Clin Biochem* 48:562-568.
8. Mubarak NA, Roubin GS, Iyer SS, Gomez CR, Liu MW, et al. (2000) Carotid stenting for severe radiation-induced extracranial carotid artery occlusive disease. *J Endovasc Ther* 7:36-40.
9. Komatsu S, Yutani C, Ohara T, Takahashi S, Takewa M, (2018) et al. (2018) Angioscopic evaluation of spontaneously ruptured aortic plaques. *J Am Coll Cardiol* 25:2893-2902.
10. Galozzi P, Bindoli S, Luisetto R, Sfriso P, Ramonda R, et al. (2021) Regulation of crystal induced inflammation: current understandings and clinical implications. *Jul Expet Rev Clin Immunol* 17:773-787.
11. Konikof FM, Chung DS, Donovan JM, Small DM, Carey MC (1992) Filamentous, helical, and tubular microstructures during cholesterol crystallization from bile. Evidence that cholesterol does not nucleate classic monohydrate plates. *J Clin Invest* 90:1155-1160.
12. Varsano N, Beghi F, Elad N, Pereiro E, Dadosh T, et al. (2018) Two polymorphic cholesterol monohydrate crystal structures form in macrophage culture models of atherosclerosis. *Proc Natl Acad Sci Unit States Am* 115:7662-7669.
13. Hirst JA, Taylor KS, Stevens RJ, Blacklock CL, Roberts NW, et al. (2012) The impact of renin-angiotensin-aldosterone system inhibitors on Type 1 and Type 2 diabetic patients with and without early diabetic nephropathy. *Kidney Int* 81:674-683.
14. Wang AY, Ho SS, Wang M, Liu EK, Ho S, et al. (2005) Cardiac valvular calcification as a marker of atherosclerosis and arterial calcification in end-stage renal disease. *Arch Intern Med* 165:327-332.
15. Hruska KA, Mathew S, Lund RJ, Menom I, Saab G, et al. (2009) The pathogenesis of vascular calcification in the chronic kidney disease mineral bone disorder: the links between bone and the vasculature. *Semin Nephrol* 29:156-165.